有価証券レコード
LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
193追跡対象保有者
+4Δ保有者数
671.92M保有株数
$804.91B報告済み評価額
+6新規ポジション
−1解消銘柄
モメンタム指標（同類マネージャー）：
保有者の広がり +2.1% ·
株式フロー -0.1% ·
新規ネットポジション数 +2.6%
— 計算式
保有の分散化 — 保有者数の増加、合計持分の縮小
すべての保有状況データ：追跡対象13Fマネージャーのみ、普通株ポジション、報告期間 Q2 2026
保有状況の推移
| 四半期 | 保有者 | Δ | 株数 | 報告済み評価額 | 新規 | 解消銘柄 |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
保有者情報 · Q2 2026
| # | 運用会社 | 株数 | Δ株式数 | 時価 | そのウェイト | 保有中 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Lilly Endowment Inc | 90.38M | -1.6% | $108.40B | 100.0% | ▼ Trim | 3 | SEC ↗ |
| 2 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 3 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 4 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 5 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 6 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 7 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 8 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 9 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 10 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 11 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 12 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 13 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 14 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 15 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 16 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 17 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 18 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 19 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 20 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 21 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 22 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 23 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 24 | BlackRock ✦ (パッシブ) | 67.54M | +1.8% | $81.01B | 1.2% | ▲ Add | 5 | SEC ↗ |
| 25 | Vanguard Capital Management Llc | 53.53M | +0.3% | $64.20B | 1.4% | ▲ Add | 2 | SEC ↗ |
| 26 | Pnc Financial Services Group, Inc. | 51.32M | 0.0% | $61.56B | 30.5% | ▼ Trim | 3 | SEC ↗ |
| 27 | Pnc Financial Services Group, Inc. | 51.32M | 0.0% | $61.56B | 30.5% | ▼ Trim | 3 | SEC ↗ |
| 28 | Pnc Financial Services Group, Inc. | 51.32M | 0.0% | $61.56B | 30.5% | ▼ Trim | 3 | SEC ↗ |
| 29 | Pnc Financial Services Group, Inc. | 51.32M | 0.0% | $61.56B | 30.5% | ▼ Trim | 3 | SEC ↗ |
| 30 | Pnc Financial Services Group, Inc. | 51.32M | 0.0% | $61.56B | 30.5% | ▼ Trim | 3 | SEC ↗ |
| 31 | Pnc Financial Services Group, Inc. | 51.32M | 0.0% | $61.56B | 30.5% | ▼ Trim | 3 | SEC ↗ |
| 32 | Pnc Financial Services Group, Inc. | 51.32M | 0.0% | $61.56B | 30.5% | ▼ Trim | 3 | SEC ↗ |
| 33 | Pnc Financial Services Group, Inc. | 51.32M | 0.0% | $61.56B | 30.5% | ▼ Trim | 3 | SEC ↗ |
| 34 | Pnc Financial Services Group, Inc. | 51.32M | 0.0% | $61.56B | 30.5% | ▼ Trim | 3 | SEC ↗ |
| 35 | Pnc Financial Services Group, Inc. | 51.32M | 0.0% | $61.56B | 30.5% | ▼ Trim | 3 | SEC ↗ |
| 36 | Pnc Financial Services Group, Inc. | 51.32M | 0.0% | $61.56B | 30.5% | ▼ Trim | 3 | SEC ↗ |
| 37 | State Street Global Advisors ✦ (パッシブ) | 36.22M | +1.7% | $43.44B | 1.3% | ▲ Add | 7 | SEC ↗ |
| 38 | Fidelity (FMR) ✦ | 28.46M | +8.1% | $34.14B | 1.5% | ▲ Add | 5 | SEC ↗ |
| 39 | Fidelity (FMR) ✦ | 28.46M | +8.1% | $34.14B | 1.5% | ▲ Add | 5 | SEC ↗ |
| 40 | Fidelity (FMR) ✦ | 28.46M | +8.1% | $34.14B | 1.5% | ▲ Add | 5 | SEC ↗ |
| 41 | Fidelity (FMR) ✦ | 28.46M | +8.1% | $34.14B | 1.5% | ▲ Add | 5 | SEC ↗ |
| 42 | Fidelity (FMR) ✦ | 28.46M | +8.1% | $34.14B | 1.5% | ▲ Add | 5 | SEC ↗ |
| 43 | Fidelity (FMR) ✦ | 28.46M | +8.1% | $34.14B | 1.5% | ▲ Add | 5 | SEC ↗ |
| 44 | Fidelity (FMR) ✦ | 28.46M | +8.1% | $34.14B | 1.5% | ▲ Add | 5 | SEC ↗ |
| 45 | Capital Research Global Investors | 20.87M | -15.3% | $25.04B | 3.5% | ▼ Trim | 3 | SEC ↗ |
| 46 | Geode Capital Management ✦ (パッシブ) | 20.31M | +0.6% | $24.28B | 1.3% | ▲ Add | 9 | SEC ↗ |
| 47 | Geode Capital Management ✦ (パッシブ) | 20.31M | +0.6% | $24.28B | 1.3% | ▲ Add | 9 | SEC ↗ |
| 48 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 49 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 50 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 51 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 52 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 53 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 54 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 55 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 56 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 57 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 58 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 59 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 60 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 61 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 62 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 63 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 64 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 65 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 66 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 67 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 68 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 69 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 70 | Morgan Stanley ✦ | 16.23M | +5.1% | $19.46B | 1.0% | ▲ Add | 4 | SEC ↗ |
| 71 | Capital World Investors ✦ | 15.90M | +1.8% | $19.08B | 2.3% | ▲ Add | 9 | SEC ↗ |
| 72 | T. Rowe Price ✦ | 13.91M | -0.6% | $16.69B | 1.7% | ▼ Trim | 9 | SEC ↗ |
| 73 | T. Rowe Price ✦ | 13.91M | -0.6% | $16.69B | 1.7% | ▼ Trim | 9 | SEC ↗ |
| 74 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 75 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 76 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 77 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 78 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 79 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 80 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 81 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 82 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 83 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 84 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 85 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 86 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 87 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 88 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 89 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 90 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 91 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 92 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 93 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 94 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 95 | JPMorgan Chase ✦ | 12.60M | -8.0% | $15.50B | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 96 | Norges Bank ✦ (パッシブ) | 11.47M | 新規 | $13.76B | 1.4% | New | 1 | SEC ↗ |
| 97 | Bank Of America Corp /De/ | 11.27M | +1.3% | $13.52B | 0.9% | ▲ Add | 3 | SEC ↗ |
| 98 | Bank Of America Corp /De/ | 11.27M | +1.3% | $13.52B | 0.9% | ▲ Add | 3 | SEC ↗ |
| 99 | Bank Of America Corp /De/ | 11.27M | +1.3% | $13.52B | 0.9% | ▲ Add | 3 | SEC ↗ |
| 100 | Bank Of America Corp /De/ | 11.27M | +1.3% | $13.52B | 0.9% | ▲ Add | 3 | SEC ↗ |
「当該ウェイト」= そのマネージャーの報告済み13F株式評価額に占めるポジションの割合（確信度の指標）。✦ = キュレーション済みマネージャー。
新規買い手
| Norges Bank | $13.76B | 1.4% |
ポジション解消済み
| Walleye Trading LLC | $4.34M | だった 0.1% |
市場全体のコンテキスト: 全13Fファイラー対象（SEC構造化データ、 Q1 2026): 4,323 保有者, 762.84M 株式数, $674.93B 報告済み. これは上記の追跡対象ユニバースの数値とは異なる、より古い期間のものであり、両者が混在することはありません。
共同保有が多い銘柄
この有価証券の追跡対象保有者が最も頻繁に保有する他の銘柄 — ファンダメンタルな関係ではなく、共同保有件数に基づきます。
市場内買い付け (P)
カバレッジ期間内にインサイダーによる市場内買い付けはありません。
市場内売却 (S)
Aug 17
Jonsson Patrik
Officer · 6.50K 株 · $7.64M
Aug 10
Zakrowski Donald A
Officer · 2.00K 株 · $2.37M
Aug 07
Hakim Anat
Officer · 5.00K 株 · $5.95M
株式付与、権利行使および税務目的の株式差し引きは、買いや売りとして集計しません。 方法論
Jul 23
SC 13G/A — LILLY ENDOWMENT INC
ニュース
Aug 24
FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test ↗
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
Forbes
Aug 24
FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly ↗
The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJ
Aug 24
Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance ↗
The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
Reuters
Aug 24
Eli Lilly Launches Foundayo Weight-Loss Pill in U.K. ↗
The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJ
Aug 23
Eli Lilly launches oral weight-loss pill Foundayo in UK ↗
Eli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2…
Reuters